Rationale of Anti-CD19 Immunotherapy: an Option to Target Autoreactive Plasma Cells in Autoimmunity

Overview

Journal Arthritis Res Ther

Publisher Biomed Central

Specialty Rheumatology

Date 2013 Jan 4

PMID 23281743

Citations 47

Authors

Henrik E Mei

Stefanie Schmidt

Thomas Dorner

Affiliations

Soon will be listed here.

Abstract

Anti-CD20 therapy using rituximab directly targeting B cells has been approved for treatment of non-Hodgkin lymphoma, rheumatoid arthritis and anti-neutrophil cytoplasmic antibody-associated vasculitides and has led to reappreciation of B-lineage cells for anti-rheumatic treatment strategies. Moreover, blocking B-cell activating factor with belimumab, a drug that is licensed for treatment of active, seropositive systemic lupus erythematosus (SLE), represents an alternative, indirect anti-B-cell approach interfering with proper B-cell development. While these approaches apparently have no substantial impact on antibody-secreting plasma cells, challenges to improve the treatment of difficult-to-treat patients with SLE remain. In this context, anti-CD19 antibodies have the promise to directly target autoantibody-secreting plasmablasts and plasma cells as well as early B-cell differentiation stages not covered by anti-CD20 therapy. Currently known distinct expression profiles of CD19 by human plasma cell subsets, experiences with anti-CD19 therapies in malignant conditions as well as the rationale of targeting autoreactive plasma cells in patients with SLE are discussed in this review.

Citing Articles

Development of Hemispherical 3D Models of Human Brain and B Cell Lymphomas Using On-Chip Cell Dome System.

Kazama R, Ishikawa R, Sakai S Bioengineering (Basel). 2025; 11(12.

PMID: 39768123 PMC: 11727638. DOI: 10.3390/bioengineering11121303.

The essential roles of memory B cells in the pathogenesis of systemic lupus erythematosus.

Dorner T, Lipsky P Nat Rev Rheumatol. 2024; 20(12):770-782.

PMID: 39511302 DOI: 10.1038/s41584-024-01179-5.

CAR-engineered T cell therapy as an emerging strategy for treating autoimmune diseases.

Vukovic J, Abazovic D, Vucetic D, Medenica S Front Med (Lausanne). 2024; 11:1447147.

PMID: 39450112 PMC: 11500465. DOI: 10.3389/fmed.2024.1447147.

Phase 1b/2a Study Assessing the Safety and Efficacy of Felzartamab in Anti-Phospholipase A2 Receptor Autoantibody-Positive Primary Membranous Nephropathy.

Rovin B, Ronco P, Wetzels J, Adler S, Ayoub I, Zaoui P Kidney Int Rep. 2024; 9(9):2635-2647.

PMID: 39291206 PMC: 11403052. DOI: 10.1016/j.ekir.2024.06.018.

Disrupting B and T-cell collaboration in autoimmune disease: T-cell engagers versus CAR T-cell therapy?.

Shah K, Leandro M, Cragg M, Kollert F, Schuler F, Klein C Clin Exp Immunol. 2024; 217(1):15-30.

PMID: 38642912 PMC: 11188544. DOI: 10.1093/cei/uxae031.

References

Gerber H, Kung-Sutherland M, Stone I, Morris-Tilden C, Miyamoto J, McCormick R . Potent antitumor activity of the anti-CD19 auristatin antibody drug conjugate hBU12-vcMMAE against rituximab-sensitive and -resistant lymphomas. Blood. 2009; 113(18):4352-61. DOI: 10.1182/blood-2008-09-179143. View

MILLER 3rd J, Cole L . Resistance of long-lived lymphocytes and plasma cells in rat lymph nodes to treatment with prednisone, cyclophosphamide, 6-mercaptopurine, and actinomycin D. J Exp Med. 1967; 126(1):109-25. PMC: 2138307. DOI: 10.1084/jem.126.1.109. View

Alexander T, Thiel A, Rosen O, Massenkeil G, Sattler A, Kohler S . Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation of a juvenile and tolerant immune system. Blood. 2008; 113(1):214-23. DOI: 10.1182/blood-2008-07-168286. View

Manz R, Thiel A, Radbruch A . Lifetime of plasma cells in the bone marrow. Nature. 1997; 388(6638):133-4. DOI: 10.1038/40540. View

Kunkel E, Butcher E . Plasma-cell homing. Nat Rev Immunol. 2003; 3(10):822-9. DOI: 10.1038/nri1203. View

Nera K, Kohonen P, Narvi E, Peippo A, Mustonen L, Terho P . Loss of Pax5 promotes plasma cell differentiation. Immunity. 2006; 24(3):283-93. DOI: 10.1016/j.immuni.2006.02.003. View

Dass S, Rawstron A, Vital E, Henshaw K, McGonagle D, Emery P . Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis. Arthritis Rheum. 2008; 58(10):2993-9. DOI: 10.1002/art.23902. View

Kochenderfer J, Feldman S, Zhao Y, Xu H, Black M, Morgan R . Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother. 2009; 32(7):689-702. PMC: 2747302. DOI: 10.1097/CJI.0b013e3181ac6138. View

Harada H, Kawano M, Huang N, Harada Y, Iwato K, TANABE O . Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993; 81(10):2658-63. View

10.

Hutloff A, Buchner K, Reiter K, Baelde H, Odendahl M, Jacobi A . Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. 2004; 50(10):3211-20. DOI: 10.1002/art.20519. View

11.

Sato S, Fujimoto M, Hasegawa M, Takehara K . Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 2004; 50(6):1918-27. DOI: 10.1002/art.20274. View

12.

Cardarelli P, Rao-Naik C, Chen S, Huang H, Pham A, Moldovan-Loomis M . A nonfucosylated human antibody to CD19 with potent B-cell depletive activity for therapy of B-cell malignancies. Cancer Immunol Immunother. 2009; 59(2):257-65. PMC: 11030752. DOI: 10.1007/s00262-009-0746-z. View

13.

Tedder T, Inaoki M, Sato S . The CD19-CD21 complex regulates signal transduction thresholds governing humoral immunity and autoimmunity. Immunity. 1997; 6(2):107-18. DOI: 10.1016/s1074-7613(00)80418-5. View

14.

Porter D, Levine B, Kalos M, Bagg A, June C . Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011; 365(8):725-33. PMC: 3387277. DOI: 10.1056/NEJMoa1103849. View

15.

Xiang Z, Cutler A, Brownlie R, Fairfax K, Lawlor K, Severinson E . FcgammaRIIb controls bone marrow plasma cell persistence and apoptosis. Nat Immunol. 2007; 8(4):419-29. DOI: 10.1038/ni1440. View

16.

Yoshida T, Mei H, Dorner T, Hiepe F, Radbruch A, Fillatreau S . Memory B and memory plasma cells. Immunol Rev. 2010; 237(1):117-39. DOI: 10.1111/j.1600-065X.2010.00938.x. View

17.

Cabanillas F, Burke J, Smith T, MOON T, Butler J, Rodriguez V . Factors predicting for response and survival in adults with advanced non-Hodgkin's lymphoma. Arch Intern Med. 1978; 138(3):413-8. View

18.

Benedetti L, Franciotta D, Vigo T, Grandis M, Fiorina E, Ghiglione E . Relapses after treatment with rituximab in a patient with multiple sclerosis and anti myelin-associated glycoprotein polyneuropathy. Arch Neurol. 2007; 64(10):1531-3. DOI: 10.1001/archneur.64.10.1531. View

19.

Isaacs J, Manna V, Rapson N, Bulpitt K, Hazleman B, Matteson E . CAMPATH-1H in rheumatoid arthritis--an intravenous dose-ranging study. Br J Rheumatol. 1996; 35(3):231-40. DOI: 10.1093/rheumatology/35.3.231. View

20.

Nutt S, Morrison A, Dorfler P, Rolink A, Busslinger M . Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 1998; 17(8):2319-33. PMC: 1170575. DOI: 10.1093/emboj/17.8.2319. View